First Time Loading...
S

Shenzhen Salubris Pharmaceuticals Co Ltd
SZSE:002294

Watchlist Manager
Shenzhen Salubris Pharmaceuticals Co Ltd
SZSE:002294
Watchlist
Price: 31.21 CNY -1.05% Market Closed
Updated: May 11, 2024
Section:
 

Relative Value

The Relative Value of one Shenzhen Salubris Pharmaceuticals Co Ltd stock under the Base Case scenario is 29.3 CNY. Compared to the current market price of 31.21 CNY, Shenzhen Salubris Pharmaceuticals Co Ltd is Overvalued by 6%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

Relative Value
Base Case
29.3 CNY
Overvaluation 6%
Relative Value
Price
S
Worst Case
Base Case
Best Case

Valuation Multiples

10.1
P/S
P/S
Price to Sales
10.1
vs History
38
vs Industry
15
Median 3Y
10.2
Median 5Y
9.6
Industry
2.5
Forward
8.5
More Details
58.7
P/E
P/E
Price to Earnings
58.7
vs History
42
vs Industry
7
Median 3Y
56.1
Median 5Y
55.5
Industry
23.4
Forward
49.8
More Details
40.6
P/OCF
P/OCF
Price to OCF
40.6
vs History
17
vs Industry
10
Median 3Y
37.5
Median 5Y
25.5
Industry
17.9
More Details
1 015.3
P/FCFE
P/FCFE
Price to FCFE
1 015.3
vs History
3
vs Industry
0
Median 3Y
132.8
Median 5Y
50.1
Industry
24.1
More Details
4.2
P/B
P/B
Price to Book Value
4.2
vs History
42
vs Industry
17
Median 3Y
4.1
Median 5Y
3.9
Industry
2.1
More Details
9.5
EV/S
EV/S
Enterprise Value to Sales
9.5
vs History
41
vs Industry
15
Median 3Y
9.6
Median 5Y
9
Industry
2.6
Forward
8
More Details
13.9
EV/GP
EV/GP
Enterprise Value to Gross Profit
13.9
vs History
34
vs Industry
15
Median 3Y
13.9
Median 5Y
12.9
Industry
5.2
More Details
50.6
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
50.6
vs History
60
vs Industry
6
Median 3Y
57.5
Median 5Y
55.2
Industry
13.9
Forward
30.5
More Details
50.6
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
50.6
vs History
60
vs Industry
7
Median 3Y
57.5
Median 5Y
55.2
Industry
17.5
Forward
43.6
More Details
38
EV/OCF
EV/OCF
Enterprise Value to OCF
38
vs History
20
vs Industry
11
Median 3Y
35.8
Median 5Y
23.7
Industry
16.4
More Details
189.5
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
189.5
vs History
12
vs Industry
3
Median 3Y
88.6
Median 5Y
48.3
Industry
18.1
More Details
4.5
EV/IC
EV/IC
Enterprise Value to IC
4.5
vs History
38
vs Industry
19
Median 3Y
4.4
Median 5Y
4.3
Industry
1.9
More Details

Multiples Across Competitors

Competitors Multiples
Shenzhen Salubris Pharmaceuticals Co Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
CN
Shenzhen Salubris Pharmaceuticals Co Ltd
SZSE:002294
34.1B CNY 10.1 58.7 50.6 50.6
JP
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
776 550.9T JPY 4 211 733 -5 347 888.9 -5 459 134.4 -5 046 864.6
US
Eli Lilly and Co
NYSE:LLY
722.3B USD 20.1 117.7 57.6 65.6
DK
Novo Nordisk A/S
CSE:NOVO B
3.9T DKK 16.1 44.1 32.9 36.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
360.8B USD 4.2 9.4 11.6 15.1
US
Merck & Co Inc
NYSE:MRK
329.4B USD 5.4 142.8 35.6 58.1
UK
AstraZeneca PLC
LSE:AZN
191.8B GBP 5 37.9 174.6 278.6
CH
Novartis AG
SIX:NOVN
180.6B CHF 3.4 11.4 8.7 12.7
CH
Roche Holding AG
SIX:ROG
179.5B CHF 3.1 15.6 8.9 10.5
US
Pfizer Inc
NYSE:PFE
158.1B USD 2.9 -511.8 12.7 20.2
P/E Multiple
Earnings Growth
CN
S
Shenzhen Salubris Pharmaceuticals Co Ltd
SZSE:002294
Average P/E: 54.7
58.7
57%
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
Negative Multiple: -5 347 888.9 N/A
US
Eli Lilly and Co
NYSE:LLY
117.7
346%
DK
Novo Nordisk A/S
CSE:NOVO B
44.1
84%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A
US
Johnson & Johnson
NYSE:JNJ
9.4
-20%
US
Merck & Co Inc
NYSE:MRK
142.8
7 454%
UK
AstraZeneca PLC
LSE:AZN
37.9
168%
CH
Novartis AG
SIX:NOVN
11.4
15%
CH
Roche Holding AG
SIX:ROG
15.6
26%
US
Pfizer Inc
NYSE:PFE
Negative Multiple: -511.8
680%

See Also

Summary
Intrinsic value, competitors valuation, and company profile.
DCF Valuation
Stock valuation using Discount Cash Flow valuation method.
Relative Valuation
Stock valuation using valuation multiples.
Wall Street Estimates
Price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
Stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
ALPHA SPREAD
Join more than 136,300+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.